<abstract xmlns="http://www.w3.org/1999/xhtml"> Tigecycline is the first agent in the new class of glycylcycline antibiotics.It’s expanded broad spectrum of activity, with demonstrated efficacy as monotherapy against clinically important Gram-positive and Gram-negative pathogens include also anerobes and antibiotic-resistant isolates.It is presented the case of a 54 years old man, recently diagnosed with HIV infection, that had high fever and skin abscesses. The laboratory investigations showed a Systemic Inflammatory Response Syndrome.After 10 days of treatment with Tygacil, 100 mg at first, then 50 mg/12 hours, surgical incision and drainage, antiinflammatory and symptomatic treatment, the patient’s symptoms disappeared and we started also the antiretroviral therapy.</abstract>

Tigecycline is the first agent in the new class of glycylcycline antibiotics.It’s expanded broad spectrum of activity, with demonstrated efficacy as monotherapy against clinically important Gram-positive and Gram-negative pathogens include also anerobes and antibiotic-resistant isolates.It is presented the case of a 54 years old man, recently diagnosed with HIV infection, that had high fever and skin abscesses. The laboratory investigations showed a Systemic Inflammatory Response Syndrome.After 10 days of treatment with Tygacil, 100 mg at first, then 50 mg/12 hours, surgical incision and drainage, antiinflammatory and symptomatic treatment, the patient’s symptoms disappeared and we started also the antiretroviral therapy.

Tigecycline For Skin Infection With SIRS In Immunocompromised Host

ARS Medica Tomitana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Tigecycline For Skin Infection With SIRS In Immunocompromised Host"}

Tigecycline is the first agent in the new class of glycylcycline antibiotics.It’s expanded broad spectrum of activity, with demonstrated efficacy as...

Tigecycline For Skin Infection With SIRS In Immunocompromised Host

Publicado en línea: 26 feb 2013

Páginas: 77 - 79

DOI: https://doi.org/10.2478/v10307-012-0015-9

Palabras clave
tigecycline, skin, systemic inflammatory response

© 2013

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Tigecycline For Skin Infection With SIRS In Immunocompromised Host

Publicado en línea: 26 feb 2013

Páginas: 77 - 79

DOI: https://doi.org/10.2478/v10307-012-0015-9

Palabras clavetigecycline, skin, systemic inflammatory response

© 2013

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
tigecycline, skin, systemic inflammatory response